SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-029210
Filing Date
2022-05-24
Accepted
2022-05-24 12:08:54
Documents
12
Period of Report
2022-05-23
Items
Item 3.02: Unregistered Sales of Equity Securities

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea160529-8k_rasnathera.htm   iXBRL 8-K 31889
  Complete submission text file 0001213900-22-029210.txt   200772

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE rasp-20220523.xsd EX-101.SCH 3024
3 XBRL LABEL FILE rasp-20220523_lab.xml EX-101.LAB 34476
4 XBRL PRESENTATION FILE rasp-20220523_pre.xml EX-101.PRE 22589
6 EXTRACTED XBRL INSTANCE DOCUMENT ea160529-8k_rasnathera_htm.xml XML 3402
Mailing Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170 646-396-4087
Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)

IRS No.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 333-191083 | Film No.: 22955056
SIC: 2834 Pharmaceutical Preparations